We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

SIGA
SIGA Technologies, Inc.
Other OTC
People also watch : PIP SCLN VICL SPPI PTIE
2.30 0.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 2.30
Open 2.29
Bid 0.00 x
Ask 0.00 x
52wk Range 0.60 - 2.55
Day's Range 2.12 - 2.30
Volume 40,188
Avg Vol (3m) 86,247
As of 3:48 PM EDT. Market closed.
  • The Wall Street Journal 6 days ago

    [$$] Siga Buying Time to Pay Off Pharmathene Debt

    Drug maker Siga Technologies hopes to avoid a takeover by former courtroom foe Pharmathene.

  • SIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016
    Capital Cube last month

    SIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016

    Click here to see latest analysisSIGA Technologies, Inc. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of SIGA Technologies, Inc. – Achillion Pharmaceuticals, Inc., Emergent BioSolutions Inc., SciClone Pharmaceuticals, Inc., Novavax, Inc., Sarepta Therapeutics, Inc., Sinovac Biotech Ltd., Chimerix, Inc., BioCryst Pharmaceuticals, Inc. and Newlink […] (Read more...) The post SIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016 appeared first on CapitalCube.

  • Forbes last month

    Court Wrestles Over Whether Gawker CEO Can Hide Behind Bankruptcy Shield

    By Maria Chutchian Gawker Media’s last-ditch effort to protect itself from a debilitating $140 million judgment using Chapter 11 may be a novel strategy to the media world but pharmaceutical and casino companies alike have recently used it with varying degrees of success. The divisive New York media giant announced Friday that

  • SIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q4, 2015 By the Numbers
    Capital Cube 3 months ago

    SIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q4, 2015 By the Numbers

    Click here to see latest analysisSIGA Technologies, Inc. reports financial results for the quarter ended December 31, 2015.HighlightsSummary numbers: Revenues of USD 4.19 million, Net Earnings of USD -20.09 million.Change in operating cash flow of -269.79% compared to same period last year is about the same as change in earnings, likely no significant movement in […] (Read more...) The post SIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q4, 2015 By the Numbers appeared first on CapitalCube.

  • Bloomberg 2 years ago

    Siga Must Pay Total of $194 Million in Smallpox-Drug Case

    Siga Technologies Inc. (SIGA) , maker of a smallpox drug to counter biological attacks, was ordered by a judge to pay more than $194 million to partner PharmAthene Inc. (PIP) in a dispute over the medicine ...

  • Reuters 2 years ago

    Delaware court orders Siga to pay PharmAthene $113 mln

    A Delaware judge on Wednesday ordered Siga Technologies Inc, a supplier of an antiviral smallpox drug to the U.S. strategic stockpile, to pay PharmAthene Inc $113.1 million in damages in a licensing dispute. ...

  • Associated Press 2 years ago

    Siga Technologies files for Ch 11 reorganization

    Drug developer Siga Technologies has filed a petition for Chapter 11 reorganization in U.S. Bankruptcy Court as it appeals a court ruling on its smallpox drug Tecovirimat. The New York company's stock ...

  • Reuters 2 years ago

    Biodefense drugmaker Siga files for bankruptcy

    The Delaware Court of Chancery had earlier ruled that PharmAthene is entitled to a lumpsum payment in damages from Siga for its failure to execute a license agreement related to its main antiviral smallpox drug, Tecovirimat, Siga said. The court did not specify the amount but Siga said in bankruptcy court documents that it expected it to be as much as $232 million. The only way to stop PharmAthene from enforcing the Chancery court's judgment and to continue operating as a going concern was to file for bankruptcy protection, Siga said on Tuesday. Siga develops drugs against diseases such as smallpox and dengue.

  • Bloomberg 2 years ago

    Siga, Smallpox Drug Supplier to U.S., Files Bankruptcy

    Siga Technologies Inc. (SIGA) , a biological warfare defense firm supplying the only smallpox drug for the U.S. Siga, which a judge ruled breached a license-negotiation contract with competitor PharmAthene Inc. (PIP) while developing the drug in 2006, filed a Chapter 11 petition today in Manhattan, listing assets of $209.5 million and debt of $197.9 million. Siga executives’ bad-faith negotiations were prompted by “seller’s remorse” over giving up control of “what was looking more and more like a multibillion-dollar drug,” Chief Justice Myron Steele wrote in a 42-page ruling at the time. The appeals court also ordered the lower-court judge to reconsider the amount of damages PharmAthene can recover, leading to an Aug. 8 preliminary ruling in Delaware Chancery Court that included a formula for calculating damages of as much as $232 million.

  • Reuters 2 years ago

    Drugmaker Siga Technologies files for bankruptcy

    Siga Technologies Inc filed for voluntary bankruptcy protection on Tuesday and said the filing was to preserve its ability to supply its antiviral smallpox drug to the U.S. Strategic National Stockpile. ...